Evidence mapPaperPMID 28465607Full record

ArticleInternational journal of obesity (2005)2017

Methods for quantifying adipose tissue insulin resistance in overweight/obese humans.

K W Ter Horst, K A van Galen, P W Gilijamse, A V Hartstra, P F de Groot, F M van der Valk, M T Ackermans, M Nieuwdorp, J A Romijn, M J Serlie

Open access · greenAbstract readValidation Study
PubMed Publisher
In one paragraph

Article in International journal of obesity (2005), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Molecular therapy. Nucleic acids · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Relationship of obesity to adipose tissue insulin resistance.BMJ open diabetes research & care · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

K W Ter HorstDepartment of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands.
K A van GalenDepartment of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands.
P W GilijamseDepartment of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands.
A V HartstraDepartment of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
P F de GrootDepartment of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
F M van der ValkDepartment of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
M T AckermansDepartment of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, Amsterdam, The Netherlands.
M NieuwdorpDepartment of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
J A RomijnDepartment of Medicine, Academic Medical Center, Amsterdam, The Netherlands.
M J SerlieDepartment of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands.
Academic Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesInsulin resistance of adipose tissue is an important feature of obesity-related metabolic disease. However, assessment of lipolysis in humans requires labor-intensive and expensive methods, and there is limited validation of simplified measurement methods. We aimed to validate simplified methods for the quantification of adipose tissue insulin resistance against the assessment of insulin sensitivity of lipolysis suppression during hyperinsulinemic-euglycemic clamp studies. SUBJECTS/

methodsWe assessed the insulin-mediated suppression of lipolysis by tracer-dilution of [1,1,2,3,3-

resultsLow-dose insulin infusion resulted in suppression of the glycerol rate of appearance ranging from 4% (most resistant) to 85% (most sensitive), indicating a good range of adipose tissue insulin sensitivity in the study population. The reference method correlated with (1) insulin-mediated suppression of plasma glycerol concentrations (r=0.960, P<0.001), (2) suppression of plasma non-esterified fatty acid (NEFA) concentrations (r=0.899, P<0.001), (3) the Adipose tissue Insulin Resistance (Adipo-IR) index (fasting plasma insulin-NEFA product; r=-0.526, P<0.001), (4) the fasting plasma insulin-glycerol product (r=-0.467, P<0.001), (5) the Adipose Tissue Insulin Resistance Index (fasting plasma insulin-basal lipolysis product; r=0.460, P<0.001), (6) the Quantitative Insulin Sensitivity Check Index (QUICKI)-NEFA index (r=0.621, P<0.001), and (7) the QUICKI-glycerol index (r=0.671, P<0.001). Bland-Altman plots showed no systematic errors for the suppression indices but proportional errors for all fasting indices. Receiver-operator characteristic curves confirmed that all indices were able to detect adipose tissue insulin resistance (area under the curve ⩾0.801, P<0.001).

conclusionsAdipose tissue insulin sensitivity (that is, the antilipolytic action of insulin) can be reliably quantified in overweight and obese humans by simplified index methods. The sensitivity and specificity of the Adipo-IR index and the fasting plasma insulin-glycerol product, combined with their simplicity and acceptable agreement, suggest that these may be most useful in clinical practice.

Indexed as

Insulin ResistanceAdipose TissueAdultBody Mass IndexFemaleGlucose Clamp TechniqueHumansHypoglycemic AgentsInsulinLipolysisMaleMetabolic SyndromeMiddle AgedObesityOverweightReference ValuesHypoglycemic AgentsInsulin

Identifiers

PMID28465607
OpenAlexW2610856332

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.